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Abstract
Background: HPV-associated HNSCCs have a distinct etiologic mechanism and better prognosis than those with
non-HPV associated HNSCCs. However, even within the each group, there is heterogeneity in survival time. Here,
we test the hypothesis that specific candidate gene methylation markers (CCNA1, NDN, CD1A, DCC, p16, GADD45A)
are associated with tumor recurrence and survival, in a well-characterized, prospective, cohort of 346 HNSCC
patients.
Methods: Kaplan-Meier curves were used to estimate survival time distributions. Multivariable Cox Proportional
Hazards models were used to test associations between each methylation marker and OST/RPFT after adjusting for
known or identified prognostic factors. Stratified Cox models included an interaction term between HPV and
methylation marker to test for differences in the associations of the biomarker with OST or RPFT across HPV status.
Results: Methylation markers were differentially associated with patient characteristics. DNA hypermethylation of
NDN and CD1A was found to be significantly associated with overall survival time (OST) in all HNSCC patients (NDN
hazard ratio (HR): 2.35, 95 % CI: 1.40-3.94; CD1A HR: 1.31, 95 % CI: 1.01-1.71). Stratification by HPV status revealed
hypermethylation of CD1A was associated with better OST and recurrence/persistence-free time (RPFT) (OST HR:
3.34, 95 % CI: 1.88-5.93; RPFT HR: 2.06, 95 % CI: 1.21-3.49), while hypomethylation of CCNA1 was associated with
increased RPFT in HPV (+) patients only (HR: 0.31, 95 % CI: 0.13-0.74).
Conclusions: This study is the first to describe novel epigenetic alterations associated with survival in an
unselected, prospectively collected, consecutive cohort of patients with HNSCC. DNA hypermethylation of NDN and
CD1A was found to be significantly associated with increased overall survival time in all HNSCC patients. However,
stratification by the important prognostic factor of HPV status revealed the immune marker, CD1A, and the cell
cycle regulator, CCNA1 to be associated with prognosis in HPV (+) patients, specifically. Here, we identified novel
methylation markers and specific, epigenetic molecular differences associated with HPV status, which warrant
further investigation.
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Background
Head and neck cancer is the 6th most common cancer in
the world with approximately 600,000 new cases each year
and at least 90 % being squamous cell carcinomas [1, 2].
Heavy tobacco and alcohol use are well established risk
factors, but high-risk human papillomavirus (HPV) infec-
tion has recently been identified as an independent etio-
logic factor for a subset of head and neck squamous cell
carcinomas (HNSCCs) [3]. The overall 5-year survival rate
for HNSCC has remained at 50-60 % for the past several
decades, primarily due to locoregional or distant meta-
static recurrence, which develop in 35- 55 % of patients
within two years [4, 5]. Low survival rates are partially due
to the fact that almost 60 % of patients are diagnosed after
the disease has advanced locally, but also due to patho-
logical, clinical and epidemiological heterogeneity [6, 7]
and frequent association of significant co-morbidities.
The incidence of HPV-associated HNSCC has steadily
increased, especially in younger patients, while incidence
of non-HPV associated HNSCC has declined in recent
years [8–10]. HPV-associated HNSCCs have a unique
risk profile, a distinct etiologic mechanism, and better
prognosis than non-HPV associated HNSCCs [11–14].
HPV (+) patients tend to have cancers almost exclusively
located in the oropharynx, be younger with a higher so-
cioeconomic status, and have a less profound use of al-
cohol and tobacco [13, 15, 16]. Studies show a 60-80 %
reduction in mortality in HPV (+) patients compared to
patients with non-HPV associated HNSCC [3, 17, 18] re-
gardless of treatment modality or tumor stage. Within
each group, however, there is heterogeneity in survival
time, with up to 20 % of HNSCCs progressing with dis-
tant metastases. Thus, there is strong interest in identify-
ing prognostic markers for both HPV (+) and HPV (-)
patients with HNSCC.
Gene-specific DNA methylation has been increas-
ingly recognized as a contributor to the molecular
heterogeneity of HNSCC [19, 20]. Several markers have
been proposed as biomarkers of prognosis and/or diagno-
sis [19, 21]. However, there is a need to determine the
validity of epigenetic markers considering the divergent
etiologic mechanisms. In addition, the extent to which ep-
idemiologic characteristics contribute to the prognostic
advantage of HPV (+) tumors is unclear. Combining
methylation information with clinical characteristics
known to affect survival is crucial to understanding the
differences in survival rates by these characteristics and
how they may be targeted for intervention.
Here we test the hypothesis that specific candidate
gene methylation markers (CCNA1, NDN, CD1A, DCC,
GADD45a, and p16) are associated with tumor recur-
rence and survival, in a well-characterized, prospective
cohort of HNSCC patients with extensive epidemiologic,
clinical and outcome information, who were treated by a
single group of clinicians with a homogenous treatment
approach. This approach allows careful consideration of
the epigenetic biomarkers in the context of epidemio-
logic and clinicopathologic characteristics that influence
overall and recurrence-free survival.
Methods
Recruitment
The University of Michigan’s Head and Neck Specialized
Program of Research Excellence (SPORE) approaches
every incident, previously untreated HNSCC patient to
participate in longitudinal epidemiology studies. This un-
selected study population represents 28 % of incident
HNSCC cases in the state of Michigan. From November
2008 through June 2012, subjects were screened for eligi-
bility and 92 % (n = 513) of subjects approached signed a
written, informed consent. Consented subjects completed
a baseline questionnaire of demographics, epidemiologic
characteristics, and behavior modules. Comorbidity data
were abstracted from the medical record and graded by
severity (none, mild, moderate, severe) using the Adult
Comorbidity Evaluation of 27 conditions organized by 12
systems (ACE-27). Research assistants collected formalin-
fixed, paraffin-embedded (FFPE) HNSCC tissue blocks
and detailed pathophysiological and clinical data annually
until death or the patient was lost to follow-up. This study
was approved by the Institutional Review Board of the
University of Michigan Medical School.
Tissue acquisition
The FFPE tissue blocks were collected pretreatment from
three possible sources: (1) a biopsy obtained from an out-
side hospital, (2) a biopsy performed at the University of
Michigan hospital, and/or (3) from surgery performed
at the University of Michigan. Tissue acquired from
the three sources yielded at least one sample for 88 %
(n = 450) of the subjects.
Study population
An expert head and neck pathologist (JM) confirmed
tumor histology and screened representative blocks
for areas of >70 % cellularity and minimal necrosis.
Seventy-two percent (n = 369) of all subjects had sufficient
tissue and DNA to yield methylation results. Of these, 15
subjects were excluded for tumors arising from rare sites
or non-squamous histology (e.g., unknown primary, naso-
pharynx, salivary gland, sinus) and 7 subjects were ex-
cluded for indeterminate HPV status. One subject was lost
to follow up. This resulted in a total of 346 subjects used
in the methylation analyses, representing 67 % of the 513
eligible participants screened.
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Follow-up
All patients were followed prospectively at designated in-
tervals by clinicians at the University of Michigan or
through contact with referring physicians. The median
follow-up period was 27 months for survival and
24 months for recurrence (range: 1-54 months). Number
of patients alive and followed for OS at 1, 2 and 3 years
were 307, 90 and 85 patients, respectively. Number of
patients alive and followed for RPFT at 1, 2 and 3 years
were 242, 129 and 53 patients, respectively. Deaths were
captured through the Social Security Death Index, yearly
survey updates, notification from family, and medical
record reviews. Survival time and events were censored as
of 4/30/13. Recurrence and persistent disease events were
confirmed updated annually during a chart review at every
subject’s yearly anniversary of their date of initial
diagnosis.
Target gene selection
Our group recently completed a discovery-based study
designed to identify novel prognostic epigenetic bio-
markers for patients with HNSCC [22, 23]. CCNA1
(cyclin A1) was chosen for further testing based on
its potential for clinical relevance and the discovery
analysis that identified regions of their promoters to
be significantly differentially methylated in head and
neck cancer patients by HPV status [22]. NDN (nec-
din) and CD1a (cluster of differentiation 1a) were also
differentially methylated in this discovery analysis,
however they were not significant, potentially due to
small sample size. NDN is an imprinted gene previ-
ously implicated in epithelial ovarian, bladder, breast,
colorectal, and urothelial cancers, as well as premalig-
nant lesions such as vulval intraepithelial neoplasia
and Barrett’s oesophagus, although has not been stud-
ied in the context of HNSCC [22–29]. CD1A was the
first immune gene found to be differentially methyl-
ated in the discovery analysis. CD1A methylation has
not been previously studied in HNSCC, however signifi-
cant hypermethylation of CD1B, CD1C, CD1D and CD1E
has been found in HPV (+) HNSCC tumors compared to
HPV(-) tumors [30]. DCC (deleted in colorectal carcin-
oma), GADD45 (growth arrest and DNA damage 45) and
p16 (cyclin-dependent kinase inhibitor) were all previously
found to be hypermethylated in HNSCC and were chosen
for their role as tumor suppressors and potential involve-
ment with HPV [9, 31–34].
Microdissection/DNA extraction/bisulfite conversion
Designated areas of FFPE tissue were microdissected
from unstained slides and DNA was extracted using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA)
according to the manufacturer’s protocol. DNA concen-
tration and purity was measured with a NanoDrop
spectrophotometer (Thermo Scientific, Waltham, MA).
Sodium bisulfite treatment was performed on 250 ng of
DNA using the Epitect Bisulfite Kit (Qiagen, Valencia,
CA) according to the manufacturer’s recommended
protocol.
HPV testing
HPV status was determined by an ultrasensitive method
using real-time competitive polymerase chain reaction
(PCR) and matrix-assisted laser desorption/ionization
mass spectroscopy, as described in Tang et al. [35].
Multiplex PCR amplification of the E6 region of 15
discrete high risk HPV types (HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, 68 and 73), and human
GAPDH control included a competitor oligo identical to
each natural amplicon except for a single nucleotide dif-
ference. Probes that identify unique sequences in the
oncogenic E6 region of each type were used in multiplex
single base extension reactions extending at the single
base difference between wild-type and competitor HPV
so that each HPV type and its competitor were distin-
guished by mass when analyzed on the MALDI-TOF
mass spectrometer as described previously [32, 36–39].
Methylation analysis
Methylation assays for promoter regions of DCC, CD1A,
GADD45 and NDN, were designed using PyroMark Assay
Design 2.0 software across 5, 2, 5 and 3 CpG sites, respect-
ively (Qiagen, Valencia, CA). The methylation assay for
p16 was adapted from Shaw, et al. and covered 4 CpG
sites [40]. The promoter region of CCNA1 was sequenced
using the Sequenom EpiTyper, a MALDI-TOF mass spec-
trometry based platform across 4 CpG sites. Primer sets
are shown in Additional file 1: Table S1. Location of each
CpG site and distance to transcription start site are de-
noted in Additional file 1: Table S2. Bisulfite singleplex
PCR amplification was performed using FastStart Taq
Polymerase (Roche Diagnostics, Indiana, US) for CCNA1,
and HotStar Taq® Master Mix Kit (Qiagen Valencia, CA)
for all other genes, with a forward and reverse primer con-
centration of 0.2 mM and 30 ng of bisulfite-converted
DNA. Confirmation of PCR product quality and absence
of contamination was established from 2 % agarose gels
with ethidium bromide staining. Fifteen microliters of
each PCR product was combined with the respective
sequencing primer and methylation analysis by pyrose-
quencing was conducted using the Pyromark™ MD System
(Biotage) according to manufacturer’s protocol, including
single strand binding protein (PyroGold reagents). Four
bisulfite and four pyrosequencing controls were generated
by mixing unmethylated and methylated control DNA
(genomic: EpigenDX; bisulfite-converted: Epitect) to ob-
tain controls with 0 %, 30 %, 60 % and 100 % methylation.
Each sample plate was run with all controls. If methylation
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values of controls were incorrect, all samples on plate
were re-run. Measurement of all samples for every methy-
lation marker selected was not possible if there was insuf-
ficient quantity of total extracted DNA. Average
methylation across all CpG sites measured for each gene
were used in all statistical analyses as strong associations
between CpG sites of each gene has been previously
shown [41].
Statistical analysis
Overall survival time (OST) and recurrence/persistence-
free time (RPFT) were calculated beginning at date of
diagnosis. An OST event was defined as death from any
cause. For RPFT, an event was defined as any recurrence
(local, regional or distant) of the tumor or persistence of
the tumor after definitive treatment. In the case of persist-
ence, an RPFT of 1 day after diagnosis was assigned. In
the case of death prior to recurrence, a subject was cen-
sored for RPFT at the last known date recurrence-free.
Univariate analyses, including Kruskal-Wallis and
Wilcoxon-rank tests, were conducted to test for differ-
ences in methylation of each gene by clinico-pathological
and epidemiological characteristics. The Kaplan-Meier
method was employed to estimate survival time distribu-
tions and graphically visualize time-to-event outcomes for
overall survival time (OST) and recurrence/persistence-
free time (RPFT) by methylation. Methylation of each
marker was categorized into quartiles for the Kaplan-
Meier curves, with quartile 1 containing the lowest values
and quartile 4 containing the highest (Additional file 1:
Table S3). Statistical differences in curves were tested
using the log-rank test.
Multivariable Cox proportional hazard models were
used to test associations between each methylation marker
and OST/RPFT after adjusting for known or identified
prognostic factors. All mean methylation values were log-
transformed after adding an offset value of 1. For each
outcome, a model with only clinical predictors was devel-
oped using a backward selection algorithm (alpha criteria
= 0.05) to arrive at a parsimonious model, with the stipula-
tion that stage and disease site would remain in the model
regardless of their significance. Variables introduced for
potential inclusion were: age, HPV status, ACE comorbid-
ity score (none, mild, moderate, severe), tobacco use
(never, former, current within 12 months), and alcohol use
(never, former, current within 12 months). The final clin-
ical model for both OST and RPFT included age, tumor
stage, disease site, and HPV; the final clinical model for
OST included comorbidity score in addition. After data
exploration, significant violation to the proportional haz-
ards assumption was observed for HPV. Stratified Cox
proportional hazard models were performed that allowed
differing baseline hazard functions for HPV+ and HPV-
groups accounting for the non-proportional hazards
observed in our data. These stratified Cox proportional
hazards models included the same adjustment covariates
as the unstratified version, and included an additional
interaction term between HPV and methylation marker to
test for differences in the associations of the biomarker
with OST or RPFT across HPV status. Finally, each
methylation marker was added to both the stratified
and un-stratified version of the clinical Cox models to
assess associations between the marker and outcome after
covariate adjustment. All methylation measurements were
standardized to interquartile ranges (IQR) of each respect-
ive marker (Additional file 1: Table S3). Therefore, hazard
ratios (HRs) are interpreted as a comparison between
those with methylation in the 25th percentile compared to
those with methylation in the 75th percentile.
Unadjusted p-values are presented, however authors
advise that a significance finding near the threshold
of p < 0.05 should be interpreted with caution. Due to
multiple tests being performed (each outcome was
modeled for 6 genes), a more conservative Bonferroni
threshold for significance was calculated as p < 0.004
(0.05/12) and reflected in superscripts in the Cox model
results (Table 4).
Statistical analyses were conducted in R 3.1.1 and
SAS 9.3.
Results
HNSCC patient characteristics
The mean age of the HNSCC patients was 59.7 years
and consisted of 75 % males (Table 1). Cancer sites were
mostly oropharyngeal and oral cavity (36 % each) while
laryngeal cancers made up about 24 % of cases and only
3 % of cases were hypopharyngeal. Sixty-one percent of
cases were stage IV. Forty-six percent of patients had
mild comorbidity status, while 26 % had moderate and
8 % had severe comorbidity. Forty-two percent of pa-
tients were classified as current smokers, or having quit
within the past 12 months, while 36 % were former
smokers (quit more than one year ago) and 22 % were
never smokers. Distributions of all patient characteristics
are listed in Table 1.
Patients with HPV (+) tumors (n = 135) were on aver-
age younger than patients with HPV (-) tumors (n = 211)
(mean age = 57 years, SD: 9.6 years for HPV (+) patients
and mean age = 61.4 years, SD: 12.3 years for HPV (-)
patients, p-value = 0.0002) (Table 2). The majority of
HPV (-) patients had cancers of the oral cavity (52 %)
whereas the majority of HPV (+) patients had cancer of
the oropharynx (OP) (78 %). HPV was detected in 22 %
of non-oropharyngeal (non OP) sites. Comparisons be-
tween HPV (+) patients presenting in OP and non-OP
sites revealed similar 2-year overall survival times
(Kaplan Meier Estimate (KM) (95 % CI): 92 % (87 %,
98 %); 89 % (77 %, 100 %); respectively, p-value = 0.71)
Virani et al. BMC Cancer  (2015) 15:825 Page 4 of 13
as well as similar recurrence-free survival times (KM
(95 % CI): 85 % (78 %, 93 %); 80 % (66 %, 98 %), respect-
ively, p-value = 0.59; Additional file 1: Figure S1) More
patients with HPV (+) tumors were diagnosed with stage
IV tumors than those patients with HPV (-) tumors
(77 % vs 51 %) primarily due to a higher frequency of pa-
tients with N2 neck disease that is common in HPV re-
lated cancers [42, 43]. Most HPV (-) patients were current
smokers (48 %) while HPV (+) patients had lower propor-
tions of current (32 %) smokers and similar frequencies of
former (37 %) and never (31 %) smokers. Pack-years of
cigarettes only use was higher in HPV (-) patients (mean:
38.4 pack-years) compared to HPV (+) patients (29.9
pack-years, p-value = 0.02). Distributions of patient char-
acteristics by HPV status are listed in Table 2.
Tumor methylation differs by epidemiologic
characteristics
Methylation of CD1A differed across clinically relevant
age groups, decreasing with increasing age (Table 3).
HPV status was significantly associated with several
markers, as expected. Methylation of CCNA1, NDN,
CD1A, and DCC was higher, while methylation of p16
was lower, in HPV (+) tumors compared to HPV (-) tu-
mors. Increasing number of total pack-years across all
tobacco types was significantly associated with decreased
methylation of NDN and CD1A. Tobacco use (current,
former, never user) was also considered separately as
these data were complete and more reliable than pack-
years for most patients (Table 3). Tobacco use was sig-
nificantly associated with methylation of NDN, CD1A,
Table 1 Patient clinical and epidemiological characteristics,
N = 346
Characteristic N (%) Mean (std),
range
Age at Dx (years) 59.7 (11.5),
25-93
Gender Male 259 75 %
Female 87 25 %
Cancer Site Larynx/Glottic 83 24 %
Oral Cavity 126 36 %
Oropharynx 125 36 %
Hypopharynx 12 3 %
Cancer Stage I/Cis 47 14 %
II 35 10 %
III 52 15 %
IV 212 61 %
Comorbidities
(ACE)
None 91 26 %
Mild 158 46 %
Moderate 70 20 %
Severe 27 8 %
HPV status Positive 135 39 %
Negative 211 61 %
Tobacco Use Current (within
past 12 months)
145 42 %
Former (quit
> 12 months)
125 36 %
Never 76 22 %
Pack Years,
n = 257
(cigs only) 35.6 (30.0),
0.1-171.0
Pack Years,
n = 264
(sum of cigs,
cigars, pipe)
37.7 (33.3),
0.07-242.9
Alcohol Use,
n = 244
Never 29 8 %
Former (quit
>12 months)
227 66 %
Current (within
past 12 months)
90 26 %
Treatment,
n = 335
Surgery alone 67 20 %
Radiation alone 34 10 %
Surgery + Radiation 34 10 %
Radiation +
Chemotherapy
138 41 %
Surgery +
Radiation +
Chemotherapy
39 12 %
No Treatment
prior to death
23 7 %
Persistent
Diseasea
29 8 %
Table 1 Patient clinical and epidemiological characteristics,
N = 346 (Continued)
Median Follow-up
for Survival
27 months
Median Follow-up
for Recurrence/
Persistence
24 months
Recurrence/
Persistenceb
81
Death 78
KM estimate
2 year RPFTc
75 %
KM estimate
2 year OSTd
79 %
aDisease considered persistent if patient never became disease free.
bRecurrence of the HNSCC in the primary, regional and/or a distant
location. Persistent patients whose disease never cleared after treatment
are included and considered recurrent with a recurrence time = 1 day. cRPFT
Recurrence/Persistent Free Time defined as time from diagnosis to recurrence
event or end of follow-up. End of follow-up is the last date where patient was
reviewed for recurrence. Patients whose disease never cleared after treatment
are considered recurrent with a recurrence time = 1 day. dOST Overall Survival
Time. Death from any cause considered an event. Overall survival time defined
from date of diagnosis by UM physician
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and DCC (p-value = 0.02; p-value < 0.001; p-value =
0.03, respectively). Interestingly, former smokers had
lower methylation of these genes compared to never or
current smokers. Trends of each methylation marker
differed significantly across disease site. Methylation of
NDN was higher in patients with higher stage tumors
(p -value < 0.001), while a trend for CCNA1 methylation
with stage was U-shaped, with higher methylation at
Table 2 Patient clinical and epidemiological characteristics by HPV status, N = 346
HPV (–) HPV (+) HPV (-) HPV (+)
Characteristic N (%) among
HPV(-)
N (%) among
HPV(+)
Mean (SD) Mean (SD) p-value
Age at Dx (years) 211 135 61.4 (12.3) 57.0 (9.6) 0.0002
Gender Male 139 66 % 120 89 % <0.0001
Female 72 34 % 15 11 %
Cancer Site Larynx/Glottic 72 34 % 11 8 % <0.0001
Oral Cavity 110 52 % 16 12 %
Oropharynx 20 9 % 105 78 %
Hypopharynx 9 4 % 3 2 %
Cancer Stage I/Cis 36 17 % 11 8 % <0.0001
II 28 13 % 7 5 %
III 39 18 % 13 10 %
IV 108 51 % 104 77 %
Comorbidities (ACE) None 41 19 % 50 37 % 0.001
Mild 99 47 % 59 44 %
Moderate 50 24 % 20 15 %
Severe 21 10 % 6 4 %
Tobacco Use Current (within
past 12 months)
102 48 % 43 32 % 0.001
Former (quit
> 12 months)
75 36 % 50 37 %
Never 34 16 % 42 31 %
Pack Years, n = 257 (cigs only) 38.4 (25.6) 29.9 (28.8) 0.02
Pack Years, n = 264 (cigs, cigars, pipe) 41.8 (34.5) 29.6 (29.4) 0.005
Alcohol Use, n = 244 Current (within
past 12 months)
63 30 % 27 20 % 0.01
Former (quit
> 12 months)
126 60 % 101 75 %
Never 22 10 % 7 5 %
Treatment, n = 335 Surg alone 53 26 % 14 11 % <0.0001
Rad alone 23 11 % 11 8 %
Surg + Rad 30 15 % 4 3 %
Rad + Chemo 45 22 % 93 70 %
Surg + Rad +
Chemo
29 14 % 10 8 %
No Treatment
prior to death
22 11 % 1 1 %
Post Treatment Status Free of Disease 186 88 % 131 97 % 0.004
Persistent Disease 25 12 % 4 3 %
KM estimate 2 year RPFT 69 % 84 % 0.001
KM estimate 2 year OST 71 % 91 % <0.0001
-Percentages will not add to 100 % horizontally. % presented is proportion of clinical or epidemiological subgroup among HPV status category. -p-values calculated by
Wilcoxon-rank tests for continuous variables and Kruskal-Wallis tests for categorical variables. Log-rank test used for KM analysis
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Table 3 Methylation markers by patient characteristics
CCNA1 NDN CD1A DCC p16 GADD45
median (range) p median (range) p median (range) p median (range) p median (range) p median (range) p
Age
<40 years 19.5 (14.5, 64.7) 0.4 40.8 (34.5, 72.8) 0.4 78.6 (56.8, 91.2)) 0.02 21.3 (9.9, 62.3) 0.4 3.1 (0.6, 25.0) 0.5 1.5 (1.0, 2.8) 0.5
40-60 25.8 (3.0, 90.5) 44.6 (10.8, 84.2) 71.0 (22.2, 93.9) 33.2 (3.1, 85.8) 2.3 (0, 70.1) 1.4 (0, 3.9)
≥60 27.3 (5.5, 77.0) 43.9 (11.2, 84.9) 68.6 (21.4, 90.9) 33.7 (3.0, 79.8) 2.2 (0, 59.8) 1.4 (0, 16.0)
HPV
Positive 33.3 (3.0, 76.0) <0.001 52.7 (14.0, 84.9) <0.001 77.6 (25.1, 93.9) <0.001 44.7 (3.1, 85.8) <0.001 1.9 (0, 59.8) <0.001 1.4 (0.4, 3.9) 0.8
Negative 20.9 (5.5, 90.5) 40.0 (10.8, 80.3) 65.4 (21.4 (92.2) 26.0 (3.0, 83.3) 2.5 (0, 70.1) 1.4 (0, 16)
Pack Years
0 26.6 (3.0, 90.5) 0.2 46.4 (14.0, 84.2) 0.01 79.7 (47.2, 93.9) <0.001 36.7 (3.1, 79.8) 0.1 2.2 (0, 26.9) 0.7 1.5 (0.3, 3.7) 0.2
0-10 31.5 (13.3, 63.3) 45.9 (24.6, 75.7) 70.5 (32.4, 91.1) 40.5 (10.8, 71.7) 2.1 (0, 46.6) 1.4 (0.4, 16.0)
10-20 23.6 (6.8, 64.8) 46.4 (10.8, 76.8) 73.0 (26.7, 91.7) 32.7 (6.1, 75.1) 2.2 (0, 70.1) 1.6 (0.7, 3.9)
20+ 25.5 (6.3, 77.0) 41.3 (11.2, 84.9) 64.2 (21.4, 92.0) 31.4 (3.0, 85.8) 2.4 (0, 59.8) 1.4 (0, 3.9)
Tobacco
Current 25.5 (6.3, 76.0) 0.8 45.0 (10.8, 84.9) 0.02 69.5 (25.1, 91.7) <0.001 39.5 (4.2, 83.3) 0.03 2.2 (0, 70.1) 0.7 1.4 (0, 16) 0.5
Former 25.6 (6.8, 77.0) 42.2 (11.2, 80.3) 64.4 (21.4, 90.0) 29.3 (3.0, 85.8) 2.4 (0, 46.6) 1.4 (0, 3.9)
Never 26.6 (3, 90.5) 46.4 (14.0, 84.2) 79.7 (47.2, 93.9) 35.7 (3.1, 79.8) 2.2 (0, 26.9) 1.5 (0.3, 3.7)
Site
Larynx/Glottic 24.5 (8.0, 90.5) <0.001 41.2 (11.2, 84.9) <0.001 56.2 (21.6, 92.2) <0.001 26.3 (3.1, 83.3) <0.001 2.4 (0, 51.8) <0.001 1.4 (0, 3.9) 0.02
Oral Cavity 22.0 (5.5, 77.0) 40.0 (10.8, 62.8) 70.6 (21.4, 90.2) 28.4 (3.0, 67.2) 2.6 (0, 70.1) 1.4 (0, 16.0)
Oropharynx 32.3 (3.0, 76.0) 52.7 (21.8, 84.2) 77.5 (21.6, 93.9) 42.5 (6.1, 81.6) 2.0 (0, 39.9) 1.4 (0.4, 3.9)
Hypopharynx 15.6 (9.0, 64.0) 44.2 (17.2, 91.0) 60.5 (25.1, 90.6) 54.5 (12.3, 85.8) 2.6 90, 59.8) 1.1 (0, 1.6)
Stage
I/Cis 27.5 (11.8, 77.0) 0.01 38.6 (11.2, 80.3) <0.001 68.1 (30.3, 89.4) 0.8 26.7 (3.0, 67.2) 0.1 2.5 (0, 39.0) 0.1 1.3 (0, 3.5) 0.3
II 22.4 (12, 74.3) 41.2 (17.2, 84.2) 68.8 (21.6, 88.3) 40.8 (7.9, 83.3) 2.3 (0, 59.8) 1.4 (0.6, 4.6)
III 21.3 (6.8, 61.3) 40.4 (15.3, 69.7) 71.2 (21.4, 90.2) 28.8 (3.9, 75.1) 2.6 (0, 70.1) 1.5 (0, 16.0)
IV 27.6 (3.0, 90.5) 46.8 (10.8, 84.9) 70.5 (21.6, 93.9) 35.9 (3.1, 85.8) 2.2 (0, 51.8) 1.4 (0, 3.9)
Comorbidities
None 29.5 (6.3, 74.3) 0.4 46.0 (20.2, 84.2) 0.3 74.8 (32.4, 93.9) 0.006 33.1 (5.6, 75.2) 0.6 2.5 (0, 39.9) 0.4 1.5 (0.4, 4.6) 0.1
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Table 3 Methylation markers by patient characteristics (Continued)
Mild 25.5 (3.0, 77.0) 43.3 (10.8, 84.9) 69.5 (21.6, 92.0) 35.4 (3.0, 85.8) 2.2 (0, 70.1) 1.4 (0, 16.0)
Moderate 23.0 (6.8, 90.5) 44.0 (15.0, 79.3) 69.2 (21.4, 92.2) 29.8 (3.5, 79.8) 2.2 (0, 59.8) 1.3 (0, 3.9)
Severe 30.5 (13.5,63.3) 44.6 (11.2, 80.3) 65.4 (21.6, 85.1) 43.0 (6.2, 83.3) 1.8 (0, 51.8) 1.2 (0, 3.9)
Gender
Male 26.5 (3.0, 90.5) 0.2 45.6 (13.0, 84.9) 0.003 69.9 (21.4, 93.9) 0.4 36.1 (3.1, 85.8) 0.002 2.3 (0, 70.1) 0.9 1.4 (0, 3.9) 0.5
Female 23.8 (6.3, 77.0) 40.5 (10.8, 68.9) 69.5 (21.6, 91.7) 25.4 (3.0, 75.1) 2.1 (0, 46.6) 1.4 (0, 16.0)
Distribution of methylation markers across patient characteristics. p-values calculated by Kruskal-Wallis tests. Methylation values are expressed as percentages
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stages I and IV (p -value = 0.01). As comorbidity status
increased, methylation of CD1A increased (p-value =
0.006). Finally, methylation of NDN and DCC was sig-
nificantly higher in males compared to females (p-value
=0.003; p-value =0.002, respectively).
Stratification by HPV status across these epidemiologic
and epigenetic characteristics revealed HPV (+) tumors
were hypermethylated across CCNA1, NDN, CD1A, and
DCC, but hypomethylated in p16 as compared to HPV(-)
tumors, regardless of clinical epidemiological traits (data
not shown).
Tumor methylation and survival/recurrence
Kaplan-Meier curves for the association between methy-
lation, categorized into quartiles, and OST and RPFT
across all HNSCC patients, are shown in Additional file
1: Figure S2. Differences in methylation of both CD1A
and NDN were significantly associated with OST in all
HNSCC patients (p-value = 0.005; p-value = 0.001, re-
spectively). The lowest quartile of methylation of CD1A
(Q1) was associated with the lowest probability of OST
(0.68 at 24 months) whereas higher methylation in Q2,
Q3 and Q4 clustered above a probability of OST of 0.80
at 24 months. Methylation of the lowest quartile of
NDN was associated with the lowest probability of OST.
In terms of RPFT, there were significant associations
with CCNA1, DCC and NDN methylation in all HNSCC
patients. NDN revealed a trend of increasing probability
of RPFT with increasing quartile of methylation. The
lowest and highest quartiles of CCNA1 and DCC had
the lowest probabilities of RPFT.
When patients were separated and analyzed by HPV sta-
tus, distinct associations between methylation markers
and OST/RPFT were identified (Additional file 1: Figures
S3 and S4). In HPV (+) patients, higher quartiles of methy-
lation of CD1A in Q3 and Q4 were associated with better
OST compared to the lower quartiles (p-value = 0.03).
Within HPV (-) patients, NDN and DCC were significantly
associated with probability of OST. Low methylation of
NDN in Q1 had the lowest probability of OST compared
to methylation in all other quartiles (p -value = 0.04). DCC
methylation in Q2 was associated with the highest prob-
ability of OST (p -value = 0.005). A similar pattern was ob-
served for DCC methylation and RPFT, although with
DCC, it was Q1 had much poorer probability of re-
currence/persistence compared to other quartiles (p-
value = 0.002). (Additional file 1: Figure S4)
NDN and CD1A methylation are novel markers of survival
in HNSCC patients
Multivariable Cox proportional hazards models adjusting
for site, stage, HPV status, age and comorbidity score
showed significant associations of NDN and CD1A gene
promoter methylation with survival in all HNSCC
Table 4 Stratified Cox Proportional Hazards Analysis comparing overall survival time (OST) and recurrence/persistence free time
(RPFT) by gene methylation
Multivariable cox model Stratified cox proportional hazards model
Gene methylationa Nb Multivariable HR (95 % CI)c,d Stratified model among HPV + c,e Stratified model among HPV-c,e p-valuef
OST CCNA1 341 1.13 (0.81, 1.59) 0.62 (0.25, 1.52) 1.25 (0.86, 1.81) 0.16
NDN 346 2.35 (1.40, 3.94) ** 3.12 (0.95, 10.21) 2.22 (1.25, 3.92)* 0.61
CD1A 342 1.31 (1.01, 1.71)* 3.34 (1.88, 5.93)** 1.13 (0.84, 1.51) 0.001**
DCC 344 1.30 (0.95, 1.78) 1.45 (0.59, 3.60) 1.28 (0.91, 1.79) 0.79
p16 343 1.11 (0.93, 1.32) 0.76 (0.48, 1.19) 1.17 (0.97, 1.42) 0.08
GADD45 340 0.88 (0.66, 1.17) 0.80 (0.43, 1.50) 0.91 (0.66, 1.25) 0.73
RPFT CCNA1 334 0.81 (0.57, 1.14) 0.31 (0.13, 0.74)* 0.96 (0.66, 1.42) 0.02*
NDN 339 1.86 (1.12, 3.07)* 2.08 (0.70, 6.19) 1.77 (1.00, 3.13) 0.79
CD1A 335 1.24 (0.95, 1.62) 2.06 (1.21, 3.49)* 1.07 (0.79, 1.46) 0.04*
DCC 337 1.32 (0.96, 1.83) 0.97 (0.40, 2.34) 1.37 (0.97, 1.94) 0.47
p16 336 1.00 (0.84, 1.19) 0.91 (0.57, 1.46) 1.00 (0.84, 1.20) 0.72
GADD45 333 1.12 (0.87, 1.46) 0.84 (0.49, 1.42) 1.23 (0.91, 1.66) 0.22
Each row represents the hazard ratios in the multivariable or stratified Cox Proportional Hazards model for each gene. The top panel lists all overall
survival time models and the bottom panel lists all recurrence/persistence-free survival time models. aAll genes log-transformed to better fit the linear
functional relationship between predictor and outcome bn number of subjects in models cAll methylation measurements standardized to interquartile
ranges. HRs are interpreted as comparison between those with methylation in the 25th percentile compared to those with methylation in the 75th percentile
dMultivariable HR calculated from a multivariable Cox Proportional Hazards model after controlling for: age, HPV status, disease site, stage, and comorbidity score in the
OST model and age, HPV status, disease site and stage in the RPFT model. eMultivariable HR (95 % CI) calculated from a stratified multivariable Cox Proportional
Hazards model to allow for differing baseline hazard functions for HPV+ and HPV- groups. These models include an interaction of HPV status and gene
methylation. Hazards listed for each HPV group in the stratified models calculated from this interaction term. Stratified OST models control for: age, disease
site, stage, and comorbidity score and stratified RPFT models control for: age, disease site and stage. fp-value for interaction term. *p-value < 0.05; **significance at the
Bonferroni-adjusted p-value < 0.004
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patients (Table 4). Treatment was not included in any
models as it was confounded by site. Those with NDN
methylation in the 25th percentile had a 2.4 times higher
hazard of a death event compared to those with methy-
lation in the 75th percentile (95 % CI: 1.40-3.94). Patients
with CD1A methylation in the 25th percentile had a 1.3
times higher hazard of a death event compared to those
with methylation in the 75th percentile upon adjustment
(95 % CI: 1.01-1.71). These results indicate that for all
HNSCC patients, hypermethylation of NDN and CD1A
are associated with better patient survival.
To determine the extent to which HPV status may have
played a role in these findings, stratified Cox models with
interaction between methylation level and HPV status
were used to measure associations separately within each
group (Table 4). Divergent associations were found in pa-
tients based on their HPV status. The test for interaction
indicated differences in OST for CD1A (p-value = 0.001)
and in RPFT for CD1A (p-value = 0.04) and CCNA1
(p-value = 0.02). In HPV (+) patients, CD1A methylation
in the 25th percentile revealed a 3.34 times higher hazard
of a death event than those in the 75th percentile (95 % CI:
1.88-5.93). In addition, patients had twice the hazard of a
tumor recurrence or persistence if they were at the 25th
percentile of CD1A methylation compared to the 75th per-
centile. These results suggest that hypermethylation of
CD1A is associated with better survival and lower recur-
rence/persistence in HPV (+) patients specifically. Con-
versely, for CCNA1, HPV (+) patients had a 0.31 times
lower hazard of a recurrent event or persistence compar-
ing those in the 25th percentile to those in the 75th per-
centile of methylation, indicating that hypomethylation of
this gene is associated with lower risk of recurrence/per-
sistence in HPV(+) patients.
Discussion
Changes in methylation patterns are one of the most fre-
quent events in human neoplasms. Epigenetic alterations
have been increasingly recognized to play a role in the
complex mechanisms of head and neck carcinogenesis
[19, 21]. This study is the first to describe novel epigenetic
alterations associated with survival in an unselected, pro-
spectively collected, consecutive cohort of patients with
HNSCC. Our strongest findings support overall survival
from HNSCC to be associated with NDN methylation in
all patients and CD1A methylation in HPV (+) patients.
These associations are significant at p-value < 0.004, the
Bonferroni-adjusted p-value for multiple testing. Despite
weaker associations, likely due to lower number of pa-
tients and events, there are indications that gene methyla-
tion is important in recurrence/persistence of HNSCC.
Hypermethylation of NDN is associated with lower recur-
rence/persistence overall whereas hypermethylation of
CD1A and hypomethylation of CCNA1 is associated with
lower recurrence/persistence in HPV (+) patients only.
These unique discoveries raise new questions about why
these specific epigenetic changes differ among biologically
distinct subsets of HNSCC patients (HPV + versus HPV -)
and if these differences are linked to HPV status or other
factors (e.g. tumor-host immunity, oncogene mutations).
NDN is a maternally imprinted gene that has monoalle-
lic expression. It encodes necdin, a protein that interacts
with p53 to suppress growth and induce cell cycle arrest
[26]. Although necdin is a p53 target gene involved in cell
growth arrest and found to be dysregulated in urothelial,
prostate, breast, bladder, lung and ovarian cancers, it has
only recently been implicated in HNSCC [22, 23, 26–30].
Our adjusted Cox model analyses revealed hypermethyla-
tion of NDN was associated with better survival in all
HNSCC patients. Although the function of NDN is un-
known, previous literature has implicated necdin to act as
a “switch”, promoting quiescence under steady state con-
ditions but bypassing p53 responses to promote prolifera-
tion or suppressing p53-induced apoptosis in a stressful
state [25, 26, 44]. Our findings support the oncogenic
function of this gene within tumor cells in that hyperme-
thylation of this gene is beneficial for patient survival.
CD1A encodes an immune protein responsible for pre-
senting antigens by dendritic Langerhans cells to T lym-
phocytes, such as natural killer cells. Findings from our
adjusted Cox model validated the difference seen in
Kaplan-Meier survival curves across quartiles of CD1A
methylation. Our analyses revealed hypermethylation was
associated with better overall survival for all HNSCC pa-
tients and, for better survival and lower recurrence in
HPV (+) patients specifically, even after adjusting for im-
portant clinical variables. Recent studies have highlighted
important differences in immunologic status in patients’
peripheral blood and tumor microenvironment according
to HPV status [45, 46]. Patients with non-HPV related
HNSCC tend to be significantly immunosuppressed and
this immune suppression is associated with worse out-
comes. CD1A dysregulation could negatively impact acti-
vation of suppressor and regulatory T cells systemically as
well as tumor associated macrophages in the microenvir-
onment, benefiting patients with HPV+ cancers. Further
studies of CD1A expression and the specific immune ab-
normalities associated with HPV status are underway.
Hypomethylation of CCNA1 was associated with lower
hazard of recurrence/persistence in HPV (+) patients
only. CCNA1 is a cell cycle regulator that binds to ret-
inoblastoma, E2F transcription factor and p21 family
proteins to promote cell cycle progression. This pathway
plays a particularly important regulatory role in cell pro-
liferation with HPV infection. Our results suggest that
decreased methylation of this cell cycle regulator is pro-
tective against recurrence events. Our findings are con-
sistent with previous findings in HPV (+) HNSCC
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patients [22, 30, 47, 48]. However, several studies have
shown that promoter methylation of CCNA1 had no effect
on protein or gene expression in HPV-positive HNSCC in
spite of a strong correlation between CCNA1 overexpres-
sion and HPV positivity, suggesting that HPV may induce
both promoter hypermethylation and overexpression
[47, 49, 50]. Prognostically, HPV induced cyclin A1 over-
expression has been associated with a lower recurrence
rate in HNSCC [47].
Considering CD1A is an immune regulatory gene and
CCNA1 is involved in response pathways to HPV infec-
tion, it is plausible that these genes would play a larger
role in more antigenic cancers with a viral etiology.
NDN, which is involved in cell cycle regulation via p53
pathways, is likely to be important in regulation of al-
tered cell cycle pathways contributing to the process of
tumorigenesis [26]. However, it remains unclear to what
extent these significant associations with survival are
due to treatment efficacy or reflect epigenetic variations
due to co-morbidities or health behaviors. In contrast to
other reports from large outcome studies, there were no
significant differences in survival outcomes with respect
to co-morbidities, suggesting that the epigenetic changes
more likely were reflective of differences in tumor biol-
ogy rather than co-morbidity. Larger epigenetic studies
of smoking, diet and co-morbidities and associations
with known genetic mutations are currently underway.
Our sensitive method of HPV detection has been previ-
ously validated with other commonly used assays to detect
HPV [39]. As expected, a majority of HPV (+) patients
presented in the oropharynx, although our use of this
assay allowed us to detect HPV in 22 % of HPV (+) pa-
tients with non-oropharynx sites, 16 % of which were in
the oral cavity. In the last decade, oral HPV prevalence
has increased in HNSCC. Previous studies have reported
prevalence of HPV in oral cavity tumors to be between 4-
20 % [3, 51–53] . This is likely explained by the significant
increase in incidence of HPV-associated oral squamous
cell carcinomas (OSCCs) since 2000, compared to the
relatively stable incidence trends of non-HPV associated
OSCCs [11]. Our cohort is a prospective, unselected pa-
tient population that is likely representing the changing
epidemiology affecting HPV-associated OSCC incidence.
This is further supported by our finding of similar 2-year
survival times of HPV (+) patients with OP and non-OP
tumors. The low proportion of HPV (+) patients with tu-
mors in the larynx and hypopharynx in our study fell
within previously reported figures [54, 55].
Epidemiologic and clinical characteristics have gener-
ally been used to understand cancer phenotype, deter-
mine prognosis and inform treatment plans for patients.
Epidemiologic factors such as smoking history, nutrition
and comorbidity are well known significant prognostic
factors for overall survival and indicate the importance
of including such factors in studies of new molecular
markers [8, 56, 57]. In the last decade, the clinical import-
ance of better understanding tumor biology in HNSCC
has emerged through validation of HPV status as a signifi-
cant molecular predictor of patient survival and recur-
rence. Differences in patient outcomes according to HPV
status are so dramatic that many investigators believe they
reflect a new and unique phenotype that could justify sig-
nificant de-intensification of therapy [8, 58]. In this study
we have identified novel methylation markers and specific,
epigenetic molecular differences within the setting of the
generalized hypermethylation phenotype associated with
HPV status, which warrant further investigation. The find-
ings support biological implications of epigenetic markers
on patient survival and their potential usefulness in identi-
fying unique subsets of patients with varied outcomes.
Several markers show expected associations with patient
characteristics. Methylation of the immune marker,
CD1A, is indicative of comorbidity status, while several
markers are differentially methylated according to HPV
status, validating our previous study [22]. However, the
finding of associations of methylation markers with char-
acteristics such as stage, gender and tobacco status is new.
Former smokers had lower methylation of NDN and
CD1A compared to never and current smokers. Because
total pack years is inversely associated with these genes,
perhaps former smokers differ because duration of expos-
ure and/or exposure at an early age is integral in the initi-
ation of processes that permits carcinogenesis.
Conclusions
Our cohort shows the expected associations established in
previous literature, such as the relationships between
stage, site and HPV status with overall survival time, and
the expected population characteristics of a HNSCC co-
hort established by previous studies, providing assurance
that the new associations with survival demonstrated with
this cohort are meaningful and can be extrapolated to the
general HNSCC patient population. Identification of sig-
nificant epigenetic markers of biologic tumor behavior
and outcome should open new horizons for investigations
and interventions directed at reversible gene alterations
and potentially identify novel therapeutic targets.
Additional file
Additional file 1: Table S1. Primer Sets and PCR Conditions for
Methylation Analysis. Table S2. CpG Locations. Table S3. Quartile
and Interquartile Ranges. Figure S1. Comparison of survival and
recurrence outcomes by HPV (+) oropharyngeal (OP) and HPV (+)
non-OP patients. Significant difference between groups is determined
by a univariable Cox Proportional Hazards model for each outcome
with a p-value <0.05. a) Probabilities of overall survival time did not
differ for OP HPV (+) patients and non-OP HPV (+) patients (p-value = 0.71).
b) Probabilities of recurrence/persistence free time did not differ for OP HPV
Virani et al. BMC Cancer  (2015) 15:825 Page 11 of 13
(+) patients and non-OP HPV (+) patients (p-value = 0.59). Figure S2.
Kaplan-Meier curves of overall survival time and recurrence-free survival time
for each methylation marker divided categorized into quartiles. Figure S3.
Kaplan- Meier curves of overall survival time for each methylation marker,
stratified by HPV status for overall survival time. Figure S4. Kaplan- Meier
curves of overall survival time for each methylation marker, stratified by HPV
status for recurrence-free survival time. (DOCX 22 kb)
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